Last reviewed · How we verify
Selinexol and Dexamethasone
Selinexol inhibits nuclear export of tumor suppressor proteins by blocking XPO1, while dexamethasone provides immunosuppressive and anti-inflammatory effects to enhance tolerability.
Selinexol inhibits nuclear export of tumor suppressor proteins by blocking XPO1, while dexamethasone provides immunosuppressive and anti-inflammatory effects to enhance tolerability. Used for Multiple myeloma, Diffuse large B-cell lymphoma (DLBCL).
At a glance
| Generic name | Selinexol and Dexamethasone |
|---|---|
| Sponsor | Beijing Friendship Hospital |
| Drug class | XPO1 inhibitor (SINE compound) combined with corticosteroid |
| Target | XPO1 (Exportin-1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Selinexol is a selective inhibitor of nuclear export (SINE) that blocks XPO1 (exportin-1), causing accumulation of tumor suppressors like p53 and IκB in the nucleus, leading to apoptosis in cancer cells. Dexamethasone, a corticosteroid, is co-administered to mitigate selinexol-induced inflammatory side effects and improve patient tolerance during treatment.
Approved indications
- Multiple myeloma
- Diffuse large B-cell lymphoma (DLBCL)
Common side effects
- Thrombocytopenia
- Nausea
- Fatigue
- Diarrhea
- Anemia
- Infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selinexol and Dexamethasone CI brief — competitive landscape report
- Selinexol and Dexamethasone updates RSS · CI watch RSS
- Beijing Friendship Hospital portfolio CI